Lucid Diagnostics (LUCD) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Meeting called to order by the Chairman and CEO, with key executives, auditors, and counsel present.
Meeting held via live webcast, with instructions for voting and submitting questions provided.
Corporate governance
Notice of internet availability of proxy materials mailed to all stockholders of record.
Certified list of stockholders as of May 29, 2024, presented and available for access.
Quorum established with majority of shares represented in person or by proxy.
Board and executive committee updates
Election of three Class C Directors (Lishan Aklog, Deborah J. White, Dennis A. Matheis) for a three-year term approved by plurality vote.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lucid Diagnostics
- Record test growth and robust clinical data set the stage for expanded coverage and revenue.LUCD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Record test volume and strong clinical data drive growth, but funding and reimbursement risks remain.LUCD
Q2 20241 Feb 2026 - Innovative pre-cancer screening and reimbursement progress set the stage for strong growth.LUCD
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 revenue up 20% to $1.2M, record test volumes, but losses and funding risks persist.LUCD
Q3 202414 Jan 2026 - Record test volume, expanded coverage, and improved cash position drive growth outlook.LUCD
Q4 202424 Dec 2025 - Offering up to $175M in securities, with ongoing losses and significant dilution risk.LUCD
Registration Filing16 Dec 2025 - Registration enables resale of 72.4M shares, with major dilution and financial risks disclosed.LUCD
Registration Filing16 Dec 2025 - Highly dilutive resale registration for 72.4M shares amid losses and Nasdaq compliance risks.LUCD
Registration Filing16 Dec 2025 - Noninvasive esophageal cancer diagnostics firm advances with new funding, but faces dilution and reimbursement risks.LUCD
Registration Filing16 Dec 2025